Atópiás dermatitisz (ekcéma): ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• JAK 7
• IL-4 1
• IL-13 2
• STAT3 1
• MAPK 0
• TNF 0
• PDE4 1
• TSLP 0
• NLRP3 0
• PPAR 0
• IL-6 0
• NRF2 0
• AKT 0
• FOXP3 0
• GLP-1 0
• HMGB1 0
• JNK 0
• STING 1
• CTLA-4 1
• ERK 0
• HSP90 0
• IL-1 0
• IL-17 0
• mTOR 0
• PI3K 0
• TYK2 0
• YAP 0
• CD19 0
• CTNNB1 0
• FAK 0
• PD-1 0
• TLR4 0
• AMPK 0
• BCL-2 0
• CD38 0
• COX-2 0
• CXCR4 0
• DPP-4 0
• EGFR 0
• FTO 0
• G6PD 0
• HIF-1 0
• IL-15 0
• IL-23 0
• MEK 0
• PD-L1 0
• PINK1 0
• PTEN 0
• RANKL 0

18+ intézményből 18, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NINDS · RF1

  The peripheral mechanisms underlying mechanical itch

  University of Michigan at Ann Arbor· Ann Arbor, Egyesült Államok· 1 397 313 USD awarded in fiscal year 2026· until 2029. aug.

• NIH NIAMS · R01

  Mechanisms of cAMP-dependent regulation of melanosome pH

  Weill Medical Coll of Cornell Univ· New York, Egyesült Államok· 551 110 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NIAMS · R01

  Regulation of epidermal differentiation via delamination and oriented cell divisions

  Univ of North Carolina Chapel Hill· Chapel Hill, Egyesült Államok· 469 412 USD awarded in fiscal year 2026· until 2031. jún.

• NIH NCCIH · R44

  AB-101: A Multi-Target Botanical Hydrogel for Combating Antimicrobial Resistance in Atopic Dermatitis

  Alphyn Biologics, Inc.· Annapolis, Egyesült Államok· 1 100 000 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NIAMS · R21

  Opioids promote wound healing in vesicant induced skin injury

  Rutgers Biomedical and Health Sciences· Newark, Egyesült Államok· 431 750 USD awarded in fiscal year 2026· until 2028. aug.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  CUtibacterium acnes metabolic engineering for Therapeutic Indole in situ delivery in atopic dermatitis SKIN (CUTISKIN)

  Imperial College of Science Technology and Medicine· London, Egyesült Királyság· EU contribution 276 188 EUR· until 2029. aug.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Positive allosteric modulators of the PD-1•PD-L1 interaction as a new mode of therapeutic intervention for autoimmune diseases: preclinical proof of concept in humanized mice (PAMinMICE)

  Vib Vzw· Zwijnaarde - Gent, Belgium· EU contribution 150 000 EUR· until 2027. febr.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Overcoming limits for pre-clinical small volume liquid delivery into skin and inflammation quantification (Lab-In-Skin)

  Universiteit Twente· Enschede, Hollandia· EU contribution 150 000 EUR· until 2026. dec.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Role of prenatal stress-induced fetal neuro-immune rewiring in susceptibility to develop pediatric eczema (PRENATALL)

  Institut National de la Sante Et de la Recherche Medicale· Paris, Franciaország· EU contribution 2 857 135 EUR· until 2029. jan.

• European Commission (Horizon Europe) · HORIZON-ERC

  Spatio-temporal integration of skin inflammation (4D-SkINFLAM)

  Deutsches Rheuma Forschungszentrumberlin· Berlin, Németország· EU contribution 2 499 188 EUR· until 2028. szept.

  The disease is named only in the funder's project summary, not in the title.

10 of 200 running projects, newest first. Listed amounts together: 119,5 M USD + 12,5 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis

  NCT05250115· Pfizer· Frissítve: 2025. szept. 29.

  “Business decision: Due to the slow recruitment, the sponsor decided to discontinue the study early.”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1

  NCT05219864· Incyte Corporation· Frissítve: 2022. nov. 17.

  “Business decision; no safety concerns.”A regiszter szövege, változtatás nélkül. Forrás

• Visszavonták

  Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 2

  NCT05233410· Incyte Corporation· Frissítve: 2022. nov. 10.

  “Business decision; no safety concerns”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis

  NCT06238817· Incyte Corporation· Forrás

• A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor

  NCT06241118· Sanofi· Forrás

• Tofacitinib for Immune Skin Conditions in Down Syndrome

  NCT04246372· University of Colorado, Denver· Forrás

• Topical Ruxolitinib Evaluation in Chronic Hand Eczema

  NCT05906628· Incyte Corporation· Forrás

• Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis

  NCT05456529· Incyte Corporation· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 17
• Organoids 2
• Mendelian Randomization Analysis 26
• Gene Expression Profiling 43
• Sequence Analysis, RNA 3
• Whole Genome Sequencing 2
• Exome Sequencing 3
• Proteomics 19
• Metabolomics 11
• Mass Spectrometry 1
• Flow Cytometry 7
• Immunohistochemistry 6
• Positron-Emission Tomography 1
• Magnetic Resonance Imaging 2
• Machine Learning 20
• Cohort Studies 65
• Genome-Wide Association Study 28

• Integration of bulk and single-cell transcriptomics with spatial analysis identifies candidate hub genes and inferred regulatory programs in atopic dermatitis.

  Front Immunol, 2026. szept.

• Sebum-associated type 17 inflammation in atopic dermatitis: a single-cell and in vivo study of body-site immune heterogeneity.

  EBioMedicine, 2026. szept.

• Eczema-like Granular Parakeratosis Exhibits Inflammatory Keratinocyte Remodeling and Aberrant Epidermal Differentiation.

  Int J Mol Sci, 2026. szept.

• A bioinformatic single-cell and structure-informed framework identifies a baicalin-CA2-keratinocyte state axis in atopic dermatitis.

  PLoS One, 2026. szept.

• scFlowReport: A Reproducible Workflow for Comparative Downstream Biological Analysis of Single-Cell RNA-seq Data.

  Biomolecules, 2026. szept.

• Type 17 T-cell subset divergence in hidradenitis suppurativa versus psoriasis: a comparative single-cell transcriptomic analysis.

  Front Immunol, 2026. aug.

• Single-cell transcriptome reveals keratinocyte subclusters contributing to altered differentiation and inflammatory responses in atopic dermatitis.

  Nat Commun, 2026. júl.

• Single-cell transcriptomic analysis identifies a MIF-driven keratinocyte-macrophage-Th2 axis as a key inflammatory circuit in atopic dermatitis.

  Inflamm Res, 2026. júl.

• Immunological differences in atopic dermatitis across age groups: insights from single-cell multi-omics.

  J Transl Med, 2026. jún.

• singIST: An integrative method for comparative single-cell transcriptomics between disease models and humans.

  PLoS Comput Biol, 2026. márc.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.